dm-101px
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 7, 2023 (NCT06037148)
Timeline
Indications
Studied for
Mechanism of action
- Immunoglobulin epsilon Fc receptorINHIBITOR
FCER2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07254871 | Phase 2 | Sep 26, 2025 | Desentum Oy |
| NCT06037148 | Phase 1 | Sep 7, 2023 | Cliantha Research Limited, Desentum Oy |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Desentum Oy | For profit | 2 | 2 | 2 | 2023 |
| Cliantha Research Limited | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1